{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:42:03Z","timestamp":1761662523922},"reference-count":135,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.cld.2007.06.012","type":"journal-article","created":{"date-parts":[[2007,8,27]],"date-time":"2007-08-27T11:10:10Z","timestamp":1188213010000},"page":"663-676","source":"Crossref","is-referenced-by-count":14,"title":["Cancer Chemotherapy II: Atypical Hepatic Injuries"],"prefix":"10.1016","volume":"11","author":[{"given":"Edmundo A.","family":"Rodriguez-Frias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2007.06.012_bib1","first-page":"219","article-title":"Allergy-induced hepatic toxicity associated with dacarbazine","volume":"71","author":"Mclay","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.cld.2007.06.012_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jso.2930270415","article-title":"VOD after dacarbazine for melanoma","volume":"27","author":"Erichsen","year":"1984","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.cld.2007.06.012_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.49.1.25","article-title":"Azathioprine induced fever, chills, rash and hepatotoxicity in rheumatoid arthritis","volume":"49","author":"Jeurissen","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cld.2007.06.012_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.1.5748.556-b","article-title":"Jaundice after treatment of leukemia with busulfan","volume":"1","author":"Underwood","year":"1971","journal-title":"Br Med J"},{"key":"10.1016\/j.cld.2007.06.012_bib5","first-page":"682","article-title":"Busulfan induced hepatitis","volume":"83","author":"Morris","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2007.06.012_bib6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0016-5085(62)80049-3","article-title":"Liver damage after chemotherapy for leukemia and lymphoma","volume":"42","author":"Amromin","year":"1962","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2007.06.012_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.7326\/0003-4819-97-1-62","article-title":"Cyclophosphamide hepatotoxicity in a patient with SLE","volume":"97","author":"Bacon","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2007.06.012_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00007611-198502000-00034","article-title":"Cyclophosphamide-associated hepatotoxicity","volume":"78","author":"Golbderg","year":"1985","journal-title":"South Med J"},{"key":"10.1016\/j.cld.2007.06.012_bib9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1572-0241.2000.01875.x","article-title":"Cumulative hepatotoxicity induced by continuous low-dose cyclophosphamide therapy","volume":"95","author":"Mok","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2007.06.012_bib10","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1007\/s10620-005-3065-z","article-title":"Acute icteric hepatitis induced by a short course of low-dose cyclophosphamide in a patient with lupus nephritis","volume":"50","author":"Muratori","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2007.06.012_bib11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1023\/A:1026514527313","article-title":"A fatal case of cholestatic liver failure probably related to gemcitabine","volume":"11","author":"Coeman","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cld.2007.06.012_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1010657609609","article-title":"Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a southwest oncology group phase II study","volume":"19","author":"Samlowski","year":"2001","journal-title":"Invest New Drugs"},{"issue":"9","key":"10.1016\/j.cld.2007.06.012_bib13","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1023\/A:1025415616592","article-title":"Fatal cholestatic liver failure associated with gemcitabine therapy","volume":"48","author":"Robinson","year":"2003","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2007.06.012_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1023\/A:1008225930573","article-title":"VOD of the liver induced by gemcitabine","volume":"9","author":"Dobbie","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cld.2007.06.012_bib15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00001813-199909000-00002","article-title":"Phase I trial of gemcitabine, 24 hour infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer","volume":"10","author":"Oettle","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cld.2007.06.012_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/oxfordjournals.annonc.a058884","article-title":"Gemcitabine in patients with advanced malignant melanoma or gastric cancer. Phase II studies of the EORTC early clinical trials group","volume":"5","author":"Sessa","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cld.2007.06.012_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jama.1964.03060350028007","article-title":"Hepatotoxicity of mercaptopurine","volume":"188","author":"Einhorn","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2007.06.012_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood.V14.1.80.80","article-title":"Hepatitis in association with prolonged 6-mercaptopurine therapy","volume":"14","author":"Mellvanic","year":"1959","journal-title":"Blood"},{"key":"10.1016\/j.cld.2007.06.012_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/bmj.1.5170.393","article-title":"Toxic complications of treatment with 6-mercaptopurine. Two cases with hepatic necrosis and intestinal ulceration","volume":"1","author":"Clark","year":"1960","journal-title":"Br Med J"},{"key":"10.1016\/j.cld.2007.06.012_bib20","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/1097-0142(197610)38:4<1524::AID-CNCR2820380413>3.0.CO;2-W","article-title":"Clinicopathologic correlation of liver damage in patients treated with 6-mercaptopurine and adriamycin","volume":"38","author":"Minow","year":"1976","journal-title":"Caner"},{"key":"10.1016\/j.cld.2007.06.012_bib21","first-page":"518","article-title":"Probable azathioprine hepatotoxicity: a case report","volume":"62","author":"Small","year":"1989","journal-title":"Ann Allergy"},{"key":"10.1016\/j.cld.2007.06.012_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/bmj.1.5897.49","article-title":"Treatment of psoriasis with azathioprine","volume":"1","author":"Duvier","year":"1974","journal-title":"Br Med J"},{"key":"10.1016\/j.cld.2007.06.012_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V32.4.507.507","article-title":"Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults","volume":"32","author":"Ellison","year":"1968","journal-title":"Blood"},{"key":"10.1016\/j.cld.2007.06.012_bib24","first-page":"1059","article-title":"Pharmacology and toxicity of high dose cytarabine by 72-hour continuous infusion","volume":"70","author":"Donehower","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.cld.2007.06.012_bib25","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/1097-0142(19841201)54:11<2360::AID-CNCR2820541109>3.0.CO;2-D","article-title":"Hepatic dysfunction and jaundice following high-dose cytosine arabinoside","volume":"54","author":"George","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.cld.2007.06.012_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mpo.2950110416","article-title":"Cytosine arabinoside induced liver damage: histopathologic demonstration","volume":"11","author":"Pizzuto","year":"1983","journal-title":"Med Pediatr Oncol"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00001813-199903000-00006","article-title":"Low-dose cytarabine-induced hepatic and renal dysfunction in a patient with myelodysplastic syndrome","volume":"10","author":"Tanaka","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cld.2007.06.012_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0016-5085(80)90205-X","article-title":"Antineoplastic agents and the liver","volume":"78","author":"Menard","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2007.06.012_bib29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0140-6736(87)91478-4","article-title":"Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukaemia","volume":"2","author":"Key","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2007.06.012_bib30","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jamcollsurg.2005.01.024","article-title":"Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on respectability of hepatic colorectal metastases","volume":"200","author":"Fernandez","year":"2005","journal-title":"J Am Coll Surg"},{"issue":"9104","key":"10.1016\/j.cld.2007.06.012_bib31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(05)78493-2","article-title":"Tamoxifen-induced fatty liver in patients with breast cancer","volume":"351","author":"Ogawa","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2007.06.012_bib32","first-page":"1103","article-title":"Tamoxifen-induced steatohepatitis","volume":"107","author":"Pratt","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2007.06.012_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(05)74872-8","article-title":"Cirrhosis with steatohepatitis after adjuvant tamoxifen","volume":"353","author":"Oien","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2007.06.012_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-124-9-199605010-00015","article-title":"Tamoxifen-induced steatohepatitis","volume":"124","author":"van Hoof","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2007.06.012_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0168-8278(95)80316-5","article-title":"Tamoxifen-associated steatohepatitis\u2013report of three cases","volume":"23","author":"Pino","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2007.06.012_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1572-0241.2000.01708.x","article-title":"Tamoxifen-induced transient multifocal hepatic fatty infiltration","volume":"95","author":"Cai","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2007.06.012_bib37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00042737-200406000-00013","article-title":"Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance","volume":"16","author":"Elefsiniotis","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7497","key":"10.1016\/j.cld.2007.06.012_bib38","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/bmj.38391.663287.E0","article-title":"Incidence and risk factors for non-alcoholic steatohepatitis: prospective trial of 5408 women enrolled in Italians tamoxifen chemoprevention trial","volume":"330","author":"Bruno","year":"2005","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.cld.2007.06.012_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1185\/030079902125001308","article-title":"Serum leptin levels are associated with tamoxifen-induced hepatic steatosis","volume":"19","author":"Gunel","year":"2003","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.cld.2007.06.012_bib40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/01.cad.0000215056.47695.92","article-title":"Fatty liver and transaminase changes with adjuvant tamoxifen therapy","volume":"17","author":"Liu","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cld.2007.06.012_bib41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0378-4274(98)00338-5","article-title":"DNA binding of tamoxifen and its analogues: identification of the tamoxifen-DNA adducts in rat liver","volume":"102\u2013103","author":"Rajaniemi","year":"1998","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.cld.2007.06.012_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF02072035","article-title":"Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens","volume":"67","author":"Hirsim\u00e4ki","year":"1993","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.cld.2007.06.012_bib43","first-page":"3919","article-title":"Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats","volume":"53","author":"Greaves","year":"1993","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.cld.2007.06.012_bib44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1046\/j.1524-4741.2002.08204.x","article-title":"Toxicity of antiestrogens","volume":"8","author":"Hirsimaki","year":"2002","journal-title":"Breast J"},{"key":"10.1016\/j.cld.2007.06.012_bib45","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ajcp\/80.6.881","article-title":"A case of peliosis hepatic in association with tamoxifen therapy","volume":"80","author":"Loomus","year":"1983","journal-title":"Am J Clin Pathol"},{"issue":"8798","key":"10.1016\/j.cld.2007.06.012_bib46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0140-6736(92)90991-B","article-title":"Tamoxifen associated hepatocellular damage and agranulocytosis","volume":"339","author":"Ching","year":"1992","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cld.2007.06.012_bib47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2169\/internalmedicine.41.345","article-title":"Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen","volume":"41","author":"Nemoto","year":"2002","journal-title":"Intern Med"},{"issue":"6","key":"10.1016\/j.cld.2007.06.012_bib48","first-page":"1119","article-title":"Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment","volume":"17","author":"Hamada","year":"2000","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.cld.2007.06.012_bib49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00280-004-0774-5","article-title":"The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women","volume":"53","author":"Jannuzzo","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.cld.2007.06.012_bib50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0090-4295(01)01252-3","article-title":"The role of diethylstilbestrol in the treatment of prostate cancer","volume":"58","author":"Malkowicz","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.cld.2007.06.012_bib51","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0016-5085(98)70590-6","article-title":"Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes","volume":"114","author":"Berson","year":"1998","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2007.06.012_bib52","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jcp.56.8.639","article-title":"Cirrhosis with steatohepatitis following long-term Stilboestrol treatment","volume":"56","author":"Cooper","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.cld.2007.06.012_bib53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1011543508731","article-title":"A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide","volume":"28","author":"Huitema","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.cld.2007.06.012_bib54","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"De Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cld.2007.06.012_bib55","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib56","first-page":"1261","article-title":"Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense","volume":"268","author":"Deleve","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cld.2007.06.012_bib57","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.bjc.6603097","article-title":"High exposures to bioactivated cyclophosphamide are related to the occurrence of VOD of the liver following high-dose chemotherapy","volume":"94","author":"De Jonge","year":"2006","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib58","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1208\/ps010314","article-title":"Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine","volume":"1","author":"Ren","year":"1999","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.cld.2007.06.012_bib59","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/annonc\/mdf052","article-title":"Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thioTEPA and carboplatin","volume":"13","author":"Huitema","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cld.2007.06.012_bib60","first-page":"119","article-title":"High dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute\/Beth Israel Hospital experience","volume":"71","author":"Antman","year":"1987","journal-title":"Cancer Treat Rep"},{"issue":"9","key":"10.1016\/j.cld.2007.06.012_bib61","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/qjmed\/hch095","article-title":"Fulminant liver failure due to severe veno-occlusive disease after haematopoietic cell transplantation: a depressing experience","volume":"97","author":"MacQuillan","year":"2004","journal-title":"QJM"},{"key":"10.1016\/j.cld.2007.06.012_bib62","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1702387","article-title":"N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation","volume":"25","author":"Ringden","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.cld.2007.06.012_bib63","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2000.18.14.2780","article-title":"Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction. Cancer and leukemia group B 9565","volume":"18","author":"Venook","year":"2000","journal-title":"J Clin Oncol"},{"issue":"6278","key":"10.1016\/j.cld.2007.06.012_bib64","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1136\/bmj.282.6278.1744","article-title":"Hepatic vascular lesions associated with dacarbazine treatment","volume":"282","author":"Greenstone","year":"1981","journal-title":"Br Med J"},{"key":"10.1016\/j.cld.2007.06.012_bib65","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/0016-5085(86)90947-9","article-title":"Azathioprine and hepatic venoocclusive disease in renal transplant patients","volume":"90","author":"Katzka","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2007.06.012_bib66","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/0016-5085(80)90911-7","article-title":"An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation","volume":"79","author":"Shulman","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2007.06.012_bib67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","article-title":"The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation","volume":"64","author":"Ohashi","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cld.2007.06.012_bib68","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","article-title":"Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Essell","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2007.06.012_bib69","first-page":"756","article-title":"Ursodiol prevention of hepatic complications in allogeneic stem cell transplantation: results of a prospective, randomized, placebo-controlled trial","volume":"23","author":"Ruutu","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cld.2007.06.012_bib70","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cld.2007.06.012_bib71","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/annonc\/mdh324","article-title":"Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome\/veno-occlusive disease","volume":"15","author":"Nabhan","year":"2004","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.cld.2007.06.012_bib72","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cld.2007.06.012_bib73","first-page":"336","article-title":"Gemtuzumab ozogamicin (Mylotarg) as a single agent to evaluate safety and determine maximum tolerated dose in post hemopoietic stem cell transplant patients with relapsed, CD 33+ acute myeloid leukemia","volume":"100","author":"Sievers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cld.2007.06.012_bib74","first-page":"871a","article-title":"Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg) with or without hematopoietic stem cell transplantation","volume":"102","author":"Erba","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cld.2007.06.012_bib75","first-page":"339a","article-title":"Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin","volume":"100","author":"Erba","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cld.2007.06.012_bib76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","article-title":"Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease","volume":"30","author":"Cohen","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.cld.2007.06.012_bib77","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin (Mylotarg) in pediatric patients with advanced CD33-positive acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cld.2007.06.012_bib78","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-2008-1072380","article-title":"Venoocclusive liver disease (VOD) as a complication of Wilms' tumor management in the series of consecutive 206 patients","volume":"10","author":"Czauderna","year":"2000","journal-title":"Eur J Pediatr Surg"},{"issue":"12","key":"10.1016\/j.cld.2007.06.012_bib79","first-page":"843","article-title":"Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma","volume":"26","author":"Sulis","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib80","first-page":"446","article-title":"Experimental model of hepatic venoocclusive disease (VOD) caused by dactinomycin-D preliminary report about hepatoprotective effect of amifostine","volume":"6","author":"Czauderna","year":"2000","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.cld.2007.06.012_bib81","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00062752-200311000-00010","article-title":"Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment","volume":"10","author":"Wadleigh","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.cld.2007.06.012_bib82","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bmt.1701172","article-title":"Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy","volume":"21","author":"Goringe","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cld.2007.06.012_bib83","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0014-2999(93)90864-E","article-title":"Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist","volume":"238","author":"Bianchi","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cld.2007.06.012_bib84","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0090-6980(90)90099-H","article-title":"Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins","volume":"40","author":"Berti","year":"1990","journal-title":"Prostaglandins"},{"key":"10.1016\/j.cld.2007.06.012_bib85","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00609244","article-title":"Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man","volume":"3","author":"Coccheri","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cld.2007.06.012_bib86","first-page":"186","article-title":"Antithrombotic effect and clinical potential of defibrotide","volume":"19","author":"Ulutin","year":"1993","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.cld.2007.06.012_bib87","first-page":"111","article-title":"Efficient prophylaxis with defibrotide for hepatic veno-occlusive disease after allogeneic stem cell transplantation","volume":"100","author":"Chalandon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cld.2007.06.012_bib88","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1046\/j.1365-2141.2000.02475.x","article-title":"Defibrotide for the treatment of hepatic veno-occlusive\u00a0disease: results of the European compassionate-use study","volume":"111","author":"Chopra","year":"2000","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.cld.2007.06.012_bib89","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00003495-200464070-00004","article-title":"The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety","volume":"64","author":"Orr","year":"2004","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib90","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(03)01010-6","article-title":"Drug increases lean tissue mass in patients with cancer","volume":"4","author":"Boughton","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cld.2007.06.012_bib91","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cpt1973145862","article-title":"Oxandrolone disposition and metabolism in man","volume":"14","author":"Karim","year":"1973","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2007.06.012_bib92","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0899-9007(01)80001-0","article-title":"Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia","volume":"17","author":"Langer","year":"2001","journal-title":"Nutrition"},{"issue":"5","key":"10.1016\/j.cld.2007.06.012_bib93","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00000421-199410000-00006","article-title":"Hepatocellular carcinoma during hormonotherapy for prostatic cancer","volume":"17","author":"Kattan","year":"1994","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cld.2007.06.012_bib94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1464-410X.1991.tb15113.x","article-title":"Hepatocellular carcinoma and treatment with cyproterone acetate","volume":"67","author":"Ohri","year":"1991","journal-title":"Br J Urol"},{"issue":"8936","key":"10.1016\/j.cld.2007.06.012_bib95","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0140-6736(94)90373-5","article-title":"Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc Committee on Androcur Users","volume":"344","author":"Watanabe","year":"1994","journal-title":"Lancet"},{"issue":"8947","key":"10.1016\/j.cld.2007.06.012_bib96","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(95)90434-4","article-title":"Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol","volume":"345","author":"Rudiger","year":"1995","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cld.2007.06.012_bib97","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/0277-5379(86)90017-9","article-title":"Hepatocellular damage by cyproterone acetate","volume":"22","author":"Meijers","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib98","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1464-410X.1991.tb15142.x","article-title":"Severe hepatocellular dysfunction following cyproterone acetate therapy","volume":"67","author":"Parys","year":"1991","journal-title":"Br J Urol"},{"issue":"2\u20133","key":"10.1016\/j.cld.2007.06.012_bib99","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1383-5742(02)00047-9","article-title":"Are some progestins genotoxic liver carcinogens?","volume":"512","author":"Brambilla","year":"2002","journal-title":"Mutat Res"},{"issue":"5","key":"10.1016\/j.cld.2007.06.012_bib100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0773.2001.d01-108.x","article-title":"Cyproterone acetate: a genotoxic carcinogen?","volume":"88","author":"Kasper","year":"2001","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.cld.2007.06.012_bib101","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/carcin\/16.10.2369","article-title":"Accumulation and persistence of DNA adducts of the synthetic steroid cyproterone acetate in rat liver","volume":"16","author":"Werner","year":"1995","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cld.2007.06.012_bib102","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0887-2333(98)80005-2","article-title":"DNA adduct formation of selected sex steroids in human liver slices in vitro","volume":"12","author":"Feser","year":"1998","journal-title":"Toxicol In Vitro"},{"key":"10.1016\/j.cld.2007.06.012_bib103","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0773.1996.tb00208.x","article-title":"Use of rat and human liver slices for the detection of steroid hormone-induced DNA adducts in vitro by means of the 32P-post-labeling technique","volume":"78","author":"Baumann","year":"1996","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.cld.2007.06.012_bib104","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/carcin\/17.3.551","article-title":"Induction of micronuclei and initiation of enzyme-altered foci in the liver of female rats treated with cyproterone acetate, chlormadinone acetate or megestrol acetate","volume":"17","author":"Martelli","year":"1996","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cld.2007.06.012_bib105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0140-6736(89)91225-7","article-title":"Fulminant hepatitis due to cyproterone acetate","volume":"1","author":"Levesque","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2007.06.012_bib106","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1445-5994.1996.tb02956.x","article-title":"Severe hepatitis and liver failure induced by cyproterone acetate","volume":"26","author":"Murphy","year":"1996","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.cld.2007.06.012_bib107","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1023\/A:1026639432428","article-title":"Fatal fulminant hepatic failure due to cyproterone acetate","volume":"44","author":"Friedman","year":"1999","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2007.06.012_bib108","first-page":"772","article-title":"Fatal subfulminant hepatitis caused by cyproterone acetate","volume":"15","author":"Antoni","year":"1991","journal-title":"Gastroenterol Clin Biol"},{"issue":"46","key":"10.1016\/j.cld.2007.06.012_bib109","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.3748\/wjg.v12.i46.7551","article-title":"Hepatotoxicity induced by cyproterone acetate: a report of three cases","volume":"12","author":"Savidou","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"32","key":"10.1016\/j.cld.2007.06.012_bib110","first-page":"1233","article-title":"Occurrence of primary hepatocellular cancer and peliosis hepatis after treatment with androgenic steroids","volume":"50","author":"Kew","year":"1976","journal-title":"S Afr Med J"},{"issue":"8","key":"10.1016\/j.cld.2007.06.012_bib111","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/BF01955250","article-title":"Hepatic tumours during androgen therapy in Fanconi anemia","volume":"152","author":"Touraine","year":"1993","journal-title":"Eur J Pediatr"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib112","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.20183","article-title":"Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions","volume":"77","author":"Velazquez","year":"2004","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib113","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF02355039","article-title":"Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature","volume":"31","author":"Kosaka","year":"1996","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cld.2007.06.012_bib114","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(02)00003-8","article-title":"Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer- a retrospective review of Chinese patients and comparison with an historic Western series","volume":"62","author":"Ma","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cld.2007.06.012_bib115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hon.2900080504","article-title":"Hepatitis B infection in patients with lymphomas","volume":"8","author":"Liang","year":"1990","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.cld.2007.06.012_bib116","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<263::AID-JMV1>3.0.CO;2-X","article-title":"Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy","volume":"59","author":"Yeo","year":"1999","journal-title":"J Med Virol"},{"key":"10.1016\/j.cld.2007.06.012_bib117","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.cld.2007.06.012_bib118","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/0003-4819-112-5-381","article-title":"Reactivation of chronic hepatitis B virus infection after discontinuation of low dose methotrexate therapy","volume":"112","author":"Hoofbagke","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2007.06.012_bib119","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archinte.1985.00360070195034","article-title":"Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier","volume":"145","author":"Thung","year":"1985","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.cld.2007.06.012_bib120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14639230500236818","article-title":"Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment","volume":"47","author":"Ikeda","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.cld.2007.06.012_bib121","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00124743-200108000-00007","article-title":"Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity","volume":"7","author":"Grismer","year":"2001","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib122","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2133.2005.06422.x","article-title":"Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis","volume":"152","author":"Chalmers","year":"2005","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib123","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2133.2005.06459.x","article-title":"Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen","volume":"152","author":"Maurice","year":"2005","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.cld.2007.06.012_bib124","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2133.1996.tb03827.x","article-title":"Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients","volume":"135","author":"Boffa","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cld.2007.06.012_bib125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1023517311879","article-title":"Chemotherapy individualization","volume":"21","author":"Veal","year":"2003","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.cld.2007.06.012_bib126","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","article-title":"Dose adjustment in patients with liver disease","volume":"28","author":"Delco","year":"2005","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.cld.2007.06.012_bib127","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00001574-199905000-00005","article-title":"Drug-induced liver disease","volume":"15","author":"Mayoral","year":"1999","journal-title":"Curr Opin Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2007.06.012_bib128","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1083-8791(99)70006-6","article-title":"Veno-occlusive disease of the liver after busulfan, melphalan and thiotepa conditioning therapy: incidence, risk factors and outcome","volume":"5","author":"Lee","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cld.2007.06.012_bib129","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","article-title":"Veno-occlusive disease of the liver after hemopoietic cell transplantation","volume":"64","author":"CarrerasS","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cld.2007.06.012_bib130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2006.02742.x","article-title":"Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome","volume":"23","author":"Helmy","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2007.06.012_bib131","first-page":"1","article-title":"Veno-occlusive disease of the liver complicating bone marrow transplant","volume":"13","author":"Baglin","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cld.2007.06.012_bib132","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1345\/aph.10220","article-title":"Prevention and treatment of veno-occlusive disease","volume":"35","author":"Pegram","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.cld.2007.06.012_bib133","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00002018-200629060-00004","article-title":"Dose adaptation of antineoplastic drugs in patients with liver disease","volume":"29","author":"Tchambaz","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.cld.2007.06.012_bib134","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev.pharmtox.41.1.101","article-title":"Pharmacogenomics: unlocking the human genome for better drug therapy","volume":"41","author":"McLeod","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.cld.2007.06.012_bib135","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326107000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326107000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T04:30:34Z","timestamp":1587875434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326107000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":135,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S1089326107000529"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2007.06.012","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}